Search for: "SANDOZ, INC." Results 481 - 500 of 679
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Nov 2010, 12:37 am by Kelly
Use of pipeline system (IP tango) EU: Notes from EU Parliament meeting on innovation+access for medical technologies (KEI) Netherlands: District Court of The Hague declares Dutch part of Bayer’s European patent covering anti-TNF alpha human monoclonal antibodies invalid (Kluwer Patent Blog) Southeast Asia: Generic drug market picks up steam in Southeast Asia, finds Front & Sullivan (GenericsWeb) Spain: Commercial Court No 5 of Barcelona: obtaining price for generic medicament an act of… [read post]
3 Nov 2010, 7:00 am
Two years later, Momenta Pharmaceuticals Inc. and its partner Sandoz, part of Novartis AG, filed. [read post]
3 Nov 2010, 1:21 am by Kelly
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
30 Sep 2010, 8:19 am by The Docket Navigator
Sandoz, Inc. et al., 1-08-cv-03710 (NYSD September 28, 2010, Memorandum Opinion & Order) (Gardephe, J.) [read post]
23 Sep 2010, 12:39 pm by FDABlog HPM
District Court for the District of Columbia challenging FDA’s September 14th approval of Watson Laboratories, Inc. [read post]
31 Aug 2010, 10:01 pm by Kelly
Apotex Inc. et al (Docket Report) Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal? [read post]
29 Aug 2010, 8:41 pm by Patent Docs
Sandoz, Inc. 1:10-cv-01057; filed August 23, 2010 in the Southern District of Indiana Infringement of U.S. [read post]
4 Aug 2010, 7:21 am
Raubicheck FDA has rejected a citizen petition filed by Sandoz, Inc. that would have required generic versions of LYRICA (pregabalin), a prescription drug approved for neuropathic pain, neuralgia and seizures, that would have barred generic applicants from carving out the pain and seizure indications to avoid infringing two Orange Book patents covering these uses. [read post]